Back to top

oncology-screening: Archive

Zacks Equity Research

Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals

Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.

RHHBYPositive Net Change DVAXNegative Net Change CORTPositive Net Change TPSTNegative Net Change

Kevin Cook

Bear of the Day: Illumina (ILMN)

Contracting margins, antitrust over GRAIL, and the Icahn invasion all crash estimates and shares

ILMNNegative Net Change

Zacks Equity Research

Waters (WAT) Boosts Mass Spectrometry Clientele With Latest Move

Waters (WAT) partners with the University of San Agustin to provide the latter with technology equipment in its newly developed mass spectrometry imaging center in the Philippines.

WATNegative Net Change ALCNegative Net Change ELANNegative Net Change

Zacks Equity Research

3D Systems (DDD) to Expand VSP Bolus Distribution With Klarity

3D Systems' (DDD) collaboration with Klarity is likely to help it in expanding the distribution of its FDA-approved VSP Bolus solution.

NVDANegative Net Change UTHRNegative Net Change DDDNegative Net Change ASURPositive Net Change

Kevin Cook

Bear of the Day: Mesa Labs (MLAB)

Mesa diagnostics gains importance among big pharma so we want to watch this dip

MLABNegative Net Change

Kevin Cook

Bull of the Day: NVIDIA (NVDA)

Sales estimates soar to $75 billion as DGX GH200 builds a moat around AI castle

NVDANegative Net Change